Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) – Equities researchers at Leerink Swann issued their Q3 2017 earnings estimates for Zai Lab Limited Unsponsored ADR in a research report issued on Monday. Leerink Swann analyst S. Fernandez expects that the company will earn ($0.17) per share for the quarter. Leerink Swann has a “Outperform” rating and a $42.00 price target on the stock. Leerink Swann also issued estimates for Zai Lab Limited Unsponsored ADR’s Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($1.25) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.23) EPS, Q3 2018 earnings at ($0.16) EPS, Q4 2018 earnings at ($0.14) EPS, FY2018 earnings at ($0.76) EPS, FY2019 earnings at ($0.79) EPS, FY2020 earnings at ($0.85) EPS and FY2021 earnings at $0.10 EPS.

WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/18/leerink-swann-weighs-in-on-zai-lab-limited-unsponsored-adrs-q3-2017-earnings-zlab.html.

A number of other equities analysts also recently issued reports on ZLAB. J P Morgan Chase & Co began coverage on Zai Lab Limited Unsponsored ADR in a research note on Monday. They issued a “neutral” rating and a $32.00 price target on the stock. Citigroup Inc. began coverage on Zai Lab Limited Unsponsored ADR in a research note on Monday. They issued a “buy” rating on the stock.

Zai Lab Limited Unsponsored ADR (ZLAB) opened at 30.84 on Wednesday. Zai Lab Limited Unsponsored ADR has a 12 month low of $23.80 and a 12 month high of $35.74. The stock’s market cap is $1.52 billion. The stock’s 50 day moving average price is $28.96 and its 200-day moving average price is $28.96.

About Zai Lab Limited Unsponsored ADR

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Earnings History and Estimates for Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

Receive News & Stock Ratings for Zai Lab Limited Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab Limited Unsponsored ADR and related stocks with our FREE daily email newsletter.